Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04661514|
Recruitment Status : Completed
First Posted : December 10, 2020
Last Update Posted : July 25, 2022
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Anorexia Nervosa||Drug: Psilocybin||Phase 2|
Because there are no proven treatments that normalize core symptoms in adult anorexia nervosa, a disorder with high chronicity, many individuals seek out alternative approaches to care. Recent evidence has suggested that anxiety, obsessive compulsive disorder, and diminished reward or motivation play key roles in the development and maintenance of dysfunctional eating, and poor outcome. In recent years, a growing number of studies have demonstrated the safety and preliminary efficacy of psilocybin in clinical trials for a range of psychiatric illnesses including treatment resistant depression, obsessive compulsive disorder, addiction, and anxiety. Psilocybin may represent a promising new treatment for anorexia nervosa. However, no studies have tested psilocybin in this eating disorder population. Accordingly, this study aims to establish the safety, tolerability and dosing of psilocybin in adult patients with anorexia nervosa, as well as gather pilot data on possible efficacy.
For this study, the investigators will recruit adults who currently have a DSM-V diagnosis of anorexia nervosa. Participants will undergo medical and psychological screening and those who are deemed eligible will partake in a maximum of 7 study visits, lasting from 4-8 weeks. On dosing day, participants will receive a single 25 mg dose of psilocybin along with psychotherapeutic support, which includes preparation and integration sessions surrounding the experience. There will be a follow-up period of one month following the psilocybin session during which a range of psychological measures (questionnaires and interviews) will be collected.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy|
|Actual Study Start Date :||May 1, 2021|
|Actual Primary Completion Date :||March 10, 2022|
|Actual Study Completion Date :||June 10, 2022|
Experimental: Safety, Tolerability, and Treatment
On dosing day, each participant will receive 1 x 25 mg treatment bottle containing 5 x 5 mg oral capsules of psilocybin. The administration session will last approximately 4-6 hours and will be supported by a lead therapist and an assisting therapist.
- Incidence and occurrence of changes in AEs [ Time Frame: Baseline to Day 28 ]
- Incidence and occurrence of changes in AEs [ Time Frame: Day 1 to Day 28 ]
- Incidence of clinically important changes in ECG parameters [ Time Frame: Baseline to Day 1 ]
- Incidence of clinically important changes in ECG parameters [ Time Frame: Baseline to Day 7 ]
- Incidence of clinically important changes in ECG parameters [ Time Frame: Baseline to Day 28 ]
- Incidence of clinically important changes in laboratory tests [ Time Frame: Baseline to Day 1 ]
- Incidence of clinically important changes in laboratory tests [ Time Frame: Baseline to Day 7 ]
- Incidence of clinically important changes in laboratory tests [ Time Frame: Baseline to Day 28 ]
- Incidence of clinically significant changes in vital signs [ Time Frame: Baseline to Day 1 ]
- Incidence of clinically significant changes in vital signs [ Time Frame: Baseline to Day 7 ]
- Incidence of clinically significant changes in vital signs [ Time Frame: Baseline to Day 28 ]
- Incidence of changes in the Columbia-Suicide Severity Rating Scale (C-SSRS) at each post-Baseline visit [ Time Frame: Baseline to Day 28 ]The C-SSRS will be used to assess suicide potential or tendency as a study entry criteria and monitored throughout the study.
- Change in Eating Disorder Examination (EDE) scores for Dietary Restraint, Eating Concern, and Shape Concern [ Time Frame: Baseline to Day 28 ]The EDE is a structured clinical interview (investigator rated) and is used to measure the severity of the characteristic psychopathology of eating disorders. The four EDE subscales (Dietary Restraint, Eating Concern, Weight Concern, and Shape Concern) are rated on a 7-point forced-choice format (0-6), with higher scores reflecting greater severity or frequency.
- Change in weight (kg) [ Time Frame: Baseline to Day 7 and Day 28 ]
- Change in trait anxiety and state anxiety total scores on the Spielberger State-Trait Anxiety Inventory (STAI) [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]The STAI consists of self-report scales for measuring "state" and "trait" anxiety. It consists of 40 items scored by a 4 point Likert scale. 20 questions refer to state anxiety, and 20 to trait anxiety thus each section is scored between 20 and 80. Higher scores indicate greater anxiety.
- Change in Physical Appearance State and Trait Anxiety Scale (PASTAS) trait total score and state score [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]The PASTAS is a self-reported 16-item measure that assesses anxiety about physical appearance. Each question is rated on a Likert scale from 0 to 4, indicating that the individual feels anxious, tense or nervous about a specific body part or general overweightness. There is a minimum score on each scale 0 and a maximum score of 64, where higher scores indicated greater severity in anxiety.
- Change in Body Image State Scale (BISS) total score [ Time Frame: Baseline to Day 28 ]The BISS is a self-report questionnaire that has six items used to assess an individual's evaluative and affecting body image state at a given moment in time. The six items are: 1) dissatisfaction with physical appearance, 2) dissatisfaction with body size and shape, 3) dissatisfaction with weight, 4) feelings of physical unattractiveness, 5) current feeling about one's look relative to how one usually feels, and 6) evaluation of one's appearance relative to how the average person looks. Each item is evaluated on a 9-point bipolar Likert like scale and higher scores indicate more positive body image.
- Change in Yale Brown Cornell Eating Disorder Scale (YBC-EDS-SRQ) [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]This self-report scale consists of 65 items and 19 question items related to eating disorder preoccupations and rituals. There is an emphasis on comparison between current state (last two weeks) and worst state, the one month where the participant believed their eating disorder to be the most severe. The scoring includes a preoccupations subtotal, rituals subtotal and total score.
- Change in Eating Disorder Inventory (EDI) total score [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]The EDI is a self-report questionnaire. It consists of 91 items organized into 12 primary scales rated on a 0-4 point scoring system, consisting of 3 eating disorder specific scales and 9 general psychological scales that are highly relevant to, but not specific to, eating disorders. It yields six composite scores: one that is eating disorder specific (i.e., Eating Disorder Risk) and five that are general integrative psychological constructs (i.e., Ineffectiveness, Interpersonal Problems, Affective Problems, Overcontrol, General Psychological Maladjustment). A computer-based scoring program generates a detailed clinical profile and scoring report for each participant.
- Change in Eating Disorder Examination Questionnaire Short Form (EDE-QS) total scores [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]The EDE-QS is a self-report questionnaire. It consists of 32 items that assess the core symptoms of eating disorders and range of eating-related psychopathology. The EDE-QS is based closely on the EDE interview. Scores range from 0 to 36 and higher scores indicate greater eating disorder symptoms.
- Change in Quick Inventory of Depressive Symptomatology (QIDS) total score [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]The QIDS is a self-reported scale. Total QIDS scores range from 0 to 27, with scores of 5 or lower indicative of no depression, scores from 6 to 10 indicating mild depression, 11 to 15 indicating moderate depression, 16 to 20 reflecting severe depression, and total scores greater than 21 indicating very severe depression.
- Change in Clinical Impairment Assessment (CIA) total scores [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]The CIA is a self-reported 16-item scale of the level of social and psychological impairment that is due to eating disorder characteristics in the past 28 days. The subscales are in mood, self-perception, cognitive functioning, interpersonal functioning and work preference. The items are rated on a Likert scale with four response categories. The scores range from 0 to 48, with a higher score indicating a higher level of impairment.
- Change in Visual Analogue Scales (VAS) measures [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]The VAS will be self-reported ratings of hunger, fullness and desire to eat and are designed specifically for this study. Participants will mark the degree of their experience in relation to anchors along a 100mm continuum.
- Change in Eating Disorder readiness to change and motivation for change (ED-RR) [ Time Frame: Baseline to Day 1, Day 7, and Day 28 ]The ED-RR is a self-reported, two-part 18-item questionnaire that examines readiness to change in nine dimensions of eating disorder behavior (restriction, weight-shape over evaluation, binge eating, vomiting, laxative use, fasting, diuretic use, weight-gain phobia, exercise). The first part measures on a Likert scale from 1-10 the subjective readiness of the patient to change. The second part measures whether the motivation to change is for others, or the self. The scale ranges from 0% (not much for me) to 100% (mostly for me). There is also an option across both parts if the participant does not engage in a particular eating disorder behavior. Higher readiness to change has shown a correlation with a decrease in eating disorder symptoms over time.
- Summary of the 5D-Altered states of consciousness questionnaire (5D-ASC) on the day of psilocybin dosing [ Time Frame: Dosing Day ]The 5D-ASC is a self-report questionnaire. It measures the acute drug effects using five primary dimensions and respective subdimensions to assess alterations in mood, perception, and experience of self in relation to environment and thought disorder. The 5 dimensions include: oceanic boundlessness, anxious ego dissolution, visionary restructuralization, auditory alterations, and reduction of vigilance. This will be administered immediately after the psilocybin session.
- Correlation between psychedelic intensity and experience and eating disorder psychopathology [ Time Frame: Dosing Day, Day 1, Day 28 ]Psychedelic intensity and experience as measured by the Five Dimension Altered States of Consciousness Questionnaire (5D-ASC); eating disorder psychopathology using the Eating Disorder Examination Questionnaire Short Form (EDE-QS)
- Patient experience and acceptability of the treatment summarized [ Time Frame: Dosing Day, Day 1, Day 28 ]Summary of patient experience and acceptability of treatment will be assessed through a qualitative interview with a therapist
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 40 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- 18 to 40 years of age at Screening
- Current diagnosis of Anorexia Nervosa (informed by DSM 5) based on medical records, clinical assessment, weight, and documented completion of the version 7.0.2 Mini International Neuropsychiatric Interview (MINI)
- Agree for the study team to maintain contact with their primary care team for the duration of the study.
- Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.
Medical exclusion criteria will be determined during the Screening Period and Baseline. Exclusion assessments that will be rechecked on the day of dosing are marked with an Asterix.
- BMI < 16 kg/m2 *
- Medical instability as indicated by significant (>3kg) weight loss during the screening period, orthostatic heart rate and blood pressure *
- Women who are pregnant, nursing, or planning a pregnancy in the near future. Male and female participants who are sexually active must agree to use a highly effective contraceptive method throughout their participation in the study. Women of child bearing potential must have a negative urine pregnancy test at Screening visits and Baseline, and psilocybin dosing session days *
- Cardiovascular conditions: recent stroke (<1 year from signing of ICF), recent myocardial infarction (<1 year from signing of ICF), uncontrolled hypertension (blood pressure >140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF.
- Uncontrolled or insulin-dependent diabetes.
- Seizure disorder.
- Use of psychedelics, including psilocybin, within one year prior to Screening assessment
- Positive urine drug screen for illicit drugs or drugs of abuse in the Screening Period and Baseline and psilocybin dosing days. Any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion *
- Current enrolment in any investigational drug or device study or participation in such within 30 days prior to Screening
- Abnormal and clinically significant results on the physical examination, vital signs, ECG, or laboratory tests at Screening, such as liver function tests (LFTs) three times greater than the upper limit of normal, reduced glomerular filtration rate (GFR) and elevated creatinin two times of upper limit of normal
- Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study
- Non-English speakers
- Current or past history of schizophrenia, psychotic disorder, bipolar disorder, significant history of mania, delusional disorder, paranoid personality disorder, schizoaffective disorder, or borderline personality disorder as assessed by medical history and a structured clinical interview
- McLean Screening Instrument for Borderline Personality Disorder >7 at Screening
- Currently taking a serotonergic medication. All serotonergic medication must be discontinued at least two weeks prior to Baseline.
- Current (within the last year) alcohol or substance use disorder as informed by DSM-5 at Screening
- Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the Colombia-Suicide Severity Rating Scale (C-SSRS) within the past year, at Screening or at Baseline, or; (2) suicidal behaviors within the past year, or; (3) clinical assessment of significant suicidal risk during subject interview (pre-treatment Baseline sessions).
- Other personal circumstances and behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin, including exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current episode.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04661514
|United States, California|
|Altman Clinical and Translational Research Institute|
|La Jolla, California, United States, 92037|
|Responsible Party:||Walter Kaye, Professor, University of California, San Diego|
|Other Study ID Numbers:||
|First Posted:||December 10, 2020 Key Record Dates|
|Last Update Posted:||July 25, 2022|
|Last Verified:||July 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Anorexia Nervosa Signs and Symptoms
Physiological Effects of Drugs
Signs and Symptoms, Digestive
Feeding and Eating Disorders
Physiological Effects of Drugs